SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-190913
Filing Date
2022-07-11
Accepted
2022-07-11 07:35:34
Documents
17
Period of Report
2022-07-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d378167d8k.htm   iXBRL 8-K 48596
2 EX-2.1 d378167dex21.htm EX-2.1 442393
3 EX-10.1 d378167dex101.htm EX-10.1 59731
4 EX-99.1 d378167dex991.htm EX-99.1 20321
8 GRAPHIC g378167g0711100751259.jpg GRAPHIC 4229
9 GRAPHIC g378167g0711100751634.jpg GRAPHIC 2963
  Complete submission text file 0001193125-22-190913.txt   843970

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20220710.xsd EX-101.SCH 2899
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20220710_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20220710_pre.xml EX-101.PRE 11290
11 EXTRACTED XBRL INSTANCE DOCUMENT d378167d8k_htm.xml XML 3447
Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 221075887
SIC: 2836 Biological Products, (No Diagnostic Substances)